Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, University of Newcastle, Newcastle, New South Wales, Australia.
Laboratory for Translational Research in Obstructive Pulmonary Diseases, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
Am J Respir Crit Care Med. 2021 Sep 15;204(6):667-681. doi: 10.1164/rccm.202009-3442OC.
Necroptosis, mediated by RIPK3 (receptor-interacting protein kinase 3) and MLKL (mixed lineage kinase domain-like), is a form of regulated necrosis that can drive tissue inflammation and destruction; however, its contribution to chronic obstructive pulmonary disease (COPD) pathogenesis is poorly understood. To determine the role of necroptosis in COPD. Total and active (phosphorylated) RIPK3 and MLKL were measured in the lung tissue of patients with COPD and control subjects without COPD. Necroptosis-related mRNA and proteins as well as cell death were examined in lungs and pulmonary macrophages of mice with cigarette smoke (CS)-induced experimental COPD. The responses of and mice to acute and chronic CS exposure were compared with those of wild-type mice. The combined inhibition of apoptosis (with the pan-caspase inhibitor quinoline-Val-Asp-difluorophenoxymethylketone [qVD-OPh]) and necroptosis (with deletion of in mice) was assessed. The total MLKL protein in the epithelium and macrophages and the pRIPK3 and pMLKL in lung tissue were increased in patients with severe COPD compared with never-smokers or smoker control subjects without COPD. Necroptosis-related mRNA and protein levels were increased in the lungs and macrophages in CS-exposed mice and experimental COPD. or deletion prevented airway inflammation upon acute CS exposure. deficiency reduced airway inflammation and remodeling as well as the development of emphysematous pathology after chronic CS exposure. deletion and qVD-OPh treatment reduced chronic CS-induced airway inflammation, but only deletion prevented airway remodeling and emphysema. or deletion and qVD-OPh treatment reduced CS-induced lung-cell death. Necroptosis is induced by CS exposure and is increased in the lungs of patients with COPD and in experimental COPD. Inhibiting necroptosis attenuates CS-induced airway inflammation, airway remodeling, and emphysema. Targeted inhibition of necroptosis is a potential therapeutic strategy in COPD.
细胞程序性坏死受 RIPK3(受体相互作用蛋白激酶 3)和 MLKL(混合谱系激酶结构域样蛋白)调控,是一种可导致组织炎症和破坏的受调控的细胞坏死形式,但人们对其在慢性阻塞性肺疾病(COPD)发病机制中的作用知之甚少。为了确定细胞程序性坏死在 COPD 中的作用,研究者检测了 COPD 患者和非 COPD 对照患者的肺组织中总 RIPK3 和活性(磷酸化)RIPK3 及 MLKL 的水平。研究者还在香烟烟雾(CS)诱导的实验性 COPD 小鼠的肺部和肺巨噬细胞中检测了与细胞程序性坏死相关的 mRNAs 和蛋白以及细胞死亡。比较了 和 小鼠对急性和慢性 CS 暴露的反应,并与野生型小鼠进行了比较。评估了联合抑制细胞凋亡(用半胱天冬酶抑制剂 quinoline-Val-Asp-difluorophenoxymethylketone [qVD-OPh])和细胞程序性坏死(用小鼠 缺失)的效果。与从不吸烟者或非 COPD 的吸烟对照者相比,严重 COPD 患者的肺上皮细胞和巨噬细胞中的总 MLKL 蛋白以及肺组织中的 pRIPK3 和 pMLKL 均增加。CS 暴露小鼠的肺部和巨噬细胞中的细胞程序性坏死相关 mRNAs 和蛋白水平均增加,并且在实验性 COPD 中也增加。在急性 CS 暴露时,或 缺失可预防气道炎症。 缺陷可减少慢性 CS 暴露后的气道炎症、重塑以及肺气肿病理的发展。 缺失和 qVD-OPh 治疗可减少慢性 CS 诱导的气道炎症,但只有 缺失可预防气道重塑和肺气肿。 缺失和 qVD-OPh 治疗可减少 CS 诱导的肺细胞死亡。CS 暴露会诱导细胞程序性坏死,并在 COPD 患者的肺部和实验性 COPD 中增加。抑制细胞程序性坏死可减轻 CS 诱导的气道炎症、气道重塑和肺气肿。靶向抑制细胞程序性坏死可能是 COPD 的一种潜在治疗策略。